Zibotentan (ZD4054)
Modify Date: 2024-01-02 11:41:42
Zibotentan (ZD4054) structure
|
Common Name | Zibotentan (ZD4054) | ||
|---|---|---|---|---|
| CAS Number | 186497-07-4 | Molecular Weight | 424.433 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 637.0±65.0 °C at 760 mmHg | |
| Molecular Formula | C19H16N6O4S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 339.0±34.3 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Zibotentan (ZD4054)Zibotentan (ZD4054) is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). IC50 value: 21 nM Target: ETA receptorZibotentan is capable of inhibiting or reducing the multitude of effects that are evoked by ET-1 activation of the ETA receptor and which promote tumor survival, growth and progression. Zibotentan (ZD4054) treatment produced significant inhibition of tumor growth in ovarian and breast xenografts. |
| Name | N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | Zibotentan (ZD4054) is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). IC50 value: 21 nM Target: ETA receptorZibotentan is capable of inhibiting or reducing the multitude of effects that are evoked by ET-1 activation of the ETA receptor and which promote tumor survival, growth and progression. Zibotentan (ZD4054) treatment produced significant inhibition of tumor growth in ovarian and breast xenografts. |
|---|---|
| Related Catalog | |
| References |
[1]. Zibotentan James, N.D., Growcott, J.W. Drugs Fut 2009, 34(8): 624. |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 637.0±65.0 °C at 760 mmHg |
| Molecular Formula | C19H16N6O4S |
| Molecular Weight | 424.433 |
| Flash Point | 339.0±34.3 °C |
| Exact Mass | 424.095367 |
| PSA | 141.37000 |
| LogP | 2.38 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.628 |
| Storage condition | -20°C |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| RTECS | UT7937700 |
|
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Schelman WR et al
Invest. New Drugs 29(1) , 118-25, (2011)
|
| N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide |
| Zd 4054 |
| S1456_Selleck |
| ZD4054 |
| Zibotentan |